These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 31894386)

  • 21. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
    Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
    Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
    Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
    Xu CW; Wang WX; Chen YP; Chen Y; Liu W; Zhong LH; Chen FF; Zhuang W; Song ZB; Chen XH; Huang YJ; Guan YF; Yi X; Lv TF; Zhu WF; Lu JP; Wang XJ; Shi Y; Lin XD; Chen G; Song Y
    J Transl Med; 2018 Apr; 16(1):93. PubMed ID: 29642919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
    Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
    Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
    Huang SH; Huang AC; Wang CC; Chang WC; Liu CY; Pavlidis S; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2019 Dec; 10(12):2274-2281. PubMed ID: 31613427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
    Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
    Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.
    Ma D; Zhang Y; Xing P; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang H; Du Y; Zhang Z; Liang L; Li J
    Thorac Cancer; 2019 May; 10(5):1213-1219. PubMed ID: 30993895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
    Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
    Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
    Gobbini E; Chiari R; Pizzutillo P; Bordi P; Ghilardi L; Pilotto S; Osman G; Cappuzzo F; Cecere F; Riccardi F; Scotti V; Martelli O; Borra G; Maiello E; Rossi A; Graziano P; Gregorc V; Casartelli C; Sergi C; Del Conte A; Delmonte A; Bareggi C; Cortinovis D; Rizzo P; Tabbò F; Rossi G; Bria E; Galetta D; Tiseo M; Di Maio M; Novello S
    Clin Transl Oncol; 2020 Mar; 22(3):294-301. PubMed ID: 31630357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.